Paclitaxel inhibits microtubule depolymerization by inhibiting mitosis in cancer cells, and the PD-L1 antibody, atezolizumab, in combination with albumin–paclitaxel was approved by the FDA as standard therapy for PD-L1-positive TNBC. The gene discussed is CD274; the disease is cancer.